Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No significant prognostic value was observed for grade, even after regrading H3F3A K27M-mutated midline glioma as grade IV (WHO 2016).
|
31419298 |
2020 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
H3 K27 mutations, most commonly in H3F3A, are common in diffuse midline glioma.
|
30864101 |
2019 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The case emphasizes the importance of comprehensive assessment based on pathological, genetic and clinical findings and calls for further investigations of non-diffuse glioma with H3F3A K27M and glioma with H3F3A K27M and BRAF V600E.
|
31254135 |
2019 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Previous data suggest that expression of transcription factors FoxG1 and Olig-2 can separate hotspot histone H3 family member 3A (H3F3A)-mutant tumours in paediatric glioma.
|
29053887 |
2018 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Frequent mutations in chromatin-modifier genes were identified including, noticeably, a truncating mutation in SETD2 (n = 4), which resulted in loss of H3K36 trimethylation and was mutually exclusive with H3F3A K27M mutation (n = 3), suggesting that epigenetic dysregulation may lead to DCG tumorigenesis.
|
28852847 |
2017 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR.
|
26376656 |
2016 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Diffuse gliomas with ATRX loss (n = 137, median 1413 days, 95 % CI: 1065-1860 days) revealed a significantly better clinical outcome compared with tumors with ATRX retention (n = 335, median: 609, 95 % CI: 539-760 days, HR = 1.81, p < 0.0001).In conclusion, ATRX is a potential marker for prediction of IDH/H3F3A mutations and substratification of diffuse gliomas into survival relevant tumor groups.
|
27311324 |
2016 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CDKN2A, and PTEN in high-grade gliomas, followed by BRAF fusions in low-grade gliomas and H3F3A mutations in pediatric gliomas.
|
26681766 |
2016 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We report a case of thalamic glioma with H3F3A K27M mutation, which was detected in both the primary tumor diagnosed as diffuse astrocytoma obtained during the first surgery and also in the tumor diagnosed as anaplastic astrocytoma obtained at the second surgery.
|
27392443 |
2016 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we sought to determine the association between H3F3A mutations and adult thalamic glioma.
|
24285547 |
2014 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We performed gene mutation analysis of IDH1 and H3 histone family 3A (H3F3A), status evaluation of glioma cytosine-phosphate-guanine island methylator phenotype (G-CIMP), and Gene Ontology analysis.
|
24997139 |
2014 |
Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.
|
23583981 |
2013 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prevalences of mutations of isocitrate dehydrogenase 1 (IDH1) and histone H3.3 (H3F3A), the glioma cytosine-phosphate-guanine island methylator phenotype (G-CIMP), and methylation of alkylpurine DNA N-glycosylase (APNG) and peroxiredoxin 1 (PRDX1) promoters were determined in a representative biomarker subset (n = 126 patients with anaplastic astrocytoma or glioblastoma) from the NOA-08 trial.
|
23595628 |
2013 |
Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.
|
22286216 |
2012 |